1. Home
  2. HOST vs XLO Comparison

HOST vs XLO Comparison

Compare HOST & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HOST

Host Digital Inc.

N/A

Current Price

$2.30

Market Cap

73.0M

Sector

N/A

ML Signal

N/A

XLO

Xilio Therapeutics Inc.

SELL

Current Price

$8.71

Market Cap

56.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HOST
XLO
Founded
2025
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.0M
56.9M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
HOST
XLO
Price
$2.30
$8.71
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $18.00
AVG Volume (30 Days)
★ 465.5K
13.4K
Earning Date
11-17-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 50.00
N/A
EPS
★ N/A
N/A
Revenue
★ $78,205,678.00
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$11.97
$23.90
P/E Ratio
N/A
★ N/A
Revenue Growth
12.74
★ 589.88
52 Week Low
$1.48
$0.46
52 Week High
$8.99
$23.80

Technical Indicators

Market Signals
Indicator
HOST
XLO
Relative Strength Index (RSI) 27.34 53.99
Support Level $1.48 $8.52
Resistance Level $3.11 $9.35
Average True Range (ATR) 0.49 0.72
MACD 0.19 0.02
Stochastic Oscillator 67.68 69.96

Price Performance

Historical Comparison
HOST
XLO

About HOST Host Digital Inc.

Host Digital Infrastructure LLC is a U.S.-based infrastructure company focused on the development and operation of power-intensive data centers designed to support high-performance computing workloads, including artificial intelligence, data processing, and other compute-intensive applications. The company focuses on securing power resources and deploying computing capacity in regions across the United States.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: